Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes

What this study is testing ClinicalTrials.gov NCT07640139 ↗

Description as written by the study sponsor.

The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers. The main questions it aims to answer are: 1. Is obesity medication usage is associated with reduced body mass index (BMI) and weight? 2. Is obesity medication usage is associated with reduced utilization of emergency department and inpatient care or obesity-related conditions over time? 3. Is obesity medication usage is associated with increased utilization of outpatient care over time? 4. Is obesity medication usage is associated with slower growth in direct medical costs over time? 5. Is obesity medication usage is associated with improvements in health measures? 6. Is obesity medication usage associated with reduced workplace costs? Researchers will compare individuals who have prescriptions for obesity medications to those without to see if differences in health and costs of care exist. The study uses existing medical and pharmacy claims data.

Treatments tested

• Incretin-based therapies (GLP-1 and GLP-1/GIP) also known as Zepbound, Tirzepatide, Wegovy, Semaglutide, Saxenda, Liraglutide Drug

  Documented receipt of any GLP-1 and GLP-1/GIP obesity medication during an observation period.